Dr. Sridharan Gururangan MD Medical Oncologist

Dr. Sridharan Gururangan is a medical oncologist in Durham, North Carolina and is affiliated with Duke University Hospital. He received his medical degree from Stanley Medical College SMC and has been in practice for 20 years. Dr. Gururangan accepts several types of health insurance, listed below. He is one of 73 doctors at Duke University Hospital who specialize in Medical Oncology. He also speaks multiple languages, including Tamil.

Are you Dr. Sridharan Gururangan? Claim your profile to make edits or add details. Edit Profile

Office Location

See Contact Information

Specialty & Clinical Interests

Medical Oncologist: General Oncology, Neuro-Oncology

Clinical Interests: Medulloblastoma, Immunotherapy, Brain Neoplasms, Clinical Trials as Topic, Drug Design

Hospital Affiliation

Duke University Hospital
Ranked #18 in Cancer

Education & Medical Training

Le Bonheur Children's Medical Center
Residency, Pediatrics, 1992 - 1993

Memorial Sloan-Kettering Cancer Center
Fellowship, Pediatric Hematology/Oncology, 1996 - 1999

St Jude Childrens Res Hospital
Fellowship, Pediatric Hematology/Oncology, 1991 - 1992

St Jude Childrens Res Hospital
Fellowship, Pediatric Hematology/Oncology, 1993 - 1994

Stanley Medical College SMC
Class of 1981

Certifications & Licensure

American Board of Pediatrics
Certified 21 years in Pediatrics

American Board of Pediatrics
Certified 14 years in Pediatric Hematology-Oncology

NC State Medical License

Publications & Presentations

Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.
Bass, J. K.,Huang, J.,Onar-Thomas, A.,Chang, K. W.,Bhagat, S. P.,Chintagumpala, M.,Bartels, U.,Gururangan, S.,Hassall, T.,Heath, J. A.,McCowage, G.,Cohn, R. J.,Fisher, M. J.,Robinson, G.,Broniscer, A.,Gajjar, A.,Gurney, J. G.

Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
Gururangan S, Fangusaro J, Poussaint TY, McLendon RE, Onar-Thomas A, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Fahey F, Vajapeyam S, Jakacki R, Gajjar A, Goldman S, Pollack IF, Friedman HS, Boyett JM, Fouladi M, Kun LE 2014 1

Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.
Gurney JG, Bass JK, Onar-Thomas A, Huang J, Chintagumpala M, Bouffet E, Hassall T, Gururangan S, Heath JA, Kellie S, Cohn R, Fisher MJ, Panandiker AP, Merchant TE, Srinivasan A, Wetmore C, Qaddoumi I, Stewart CF, Armstrong GT, Broniscer A, Gajjar A 2014 1 16

See all 97 publications

Insurances Accepted

  • Aetna Choice POS II
  • Aetna HMO
  • BCBS Blue Card PPO
  • BCBS California PPO
  • BCBS Kansas City Preferred-Care Blue PPO
  • BCBS North Carolina BlueOptions PPO
  • Blue Shield California PPO
  • CIGNA Open Access
  • First Health PPO
  • Great West PPO
  • Health Net California Large Group PPO
  • Humana ChoiceCare Network PPO
  • Multiplan PHCS PPO
  • Multiplan PPO
  • United Healthcare - Direct Choice Plus POS
  • United Healthcare - Direct Options PPO
Find More Doctors
Doctor Finder

Our Doctor Finder includes most U.S. physicians. Doctors are not ranked, learn more.

Browse Doctors by



Search all Doctors

Profiles by Doximity

Your Message Has Been Submitted

As part of our research on the correction you submitted, you may be contacted at the email address provided.

Sorry, Your Message Could Not Be Submitted

Please try again later, or E-mail your message to doctors@usnews.com and include the Web address (URL) of the page that contains incorrect information.